Overview
Cibus Q3 revenue misses analyst expectations, reporting $615,000 compared to $1.39 mln estimate
Net loss for Q3 was $24.3 mln, significantly lower than $201.5 mln last year
Company focuses on strategic partnerships and cost reductions to support future growth
Outlook
Cibus targets initial commercial launch of rice traits in Latin America by 2027
Company plans commercial expansion of Sustainable Ingredients program in 2026
Cibus aims to reduce annual net cash usage to $30 mln by 2026
Result Drivers
LATAM EXPANSION - Cibus continues to progress with herbicide tolerance traits in Rice, targeting initial commercial launches in Latin America by 2027
INDIA MARKET ENTRY - Cibus engaged AgVayā to support entry into Indian market for advanced gene editing solutions
BIOFRAGRANCE PILOT - Successfully completed pre-commercial pilot runs for biofragrance products, targeting commercial expansion in 2026
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $615,000 | $1.39 mln (3 Analysts) |
Q3 EPS | -$0.44 | ||
Q3 Net Income | -$24.30 mln | ||
Q3 Income from Operations | -$15.44 mln | ||
Q3 Operating Expenses | $16.05 mln | ||
Q3 Pretax Profit | -$24.31 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cibus Inc is $15.50, about 91.3% above its November 12 closing price of $1.35
Press Release: ID:nGNX3yN8qv
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)